Welcome to Tumorimmunology
The Kuball Laboratory Tumorimmunolgy team develop innovative treatment strategies for improving the outcome and treatment of hematological cancers.
Welcome to Tumorimmunology
The Kuball Laboratory Tumorimmunolgy team develop innovative treatment strategies for improving the outcome and treatment of hematological cancers.
OUR MISSION:
CURING CANCER WHILE ALSO IMPROVING QUALITY OF LIFE
Kuball Laboratories stands at the forefront of cancer research and immunotherapy, pioneering a multi-faceted approach to combat cancer through innovative immune receptor and co-stimulation techniques, next-generation predictive models, soluble formats for therapeutic applications, and the development of advanced therapy medicinal products (ATMPs). With a keen focus on translating academic research into clinical successes, the laboratory's comprehensive expertise facilitates rapid drug development from initial discovery to clinical application.
Innate Immune Receptor and Co-stimulation: Led by Prof. Dr. Jürgen Kuball, the team harnesses the power of γδT cells and their receptors for cancer cell therapy. Kuball's work emphasizes the therapeutic potential of individual receptors derived from γδT cells, which display potent recognition towards a variety of tumors with even low mutation load while preserving normal tissues.
Next-Generation Prediction Models: Under the guidance of Associate Professor Dr. Zsolt Sebestyen develops cutting-edge 3D models and other predictive tools to enhance our understanding of cancer and its treatment. This includes exploring the diversity and functions of immune effector cells of different origin with multiomics approaches utilizing artificial intelligence, aiming to optimize their therapeutic application and make early judgment calls on different leads with the highest potency for clinical translation.
Soluble Formats for Therapeutic Applications: Assistant Prof. Dr. Dennis Beringer leads efforts in creating bispecific T cell engagers based on innate immune receptors that leverage the unique capabilities of immune cells for targeted cancer therapy. This innovative approach seeks to design protein based immune therapies to refine and enhance the efficiencies of immune therapeutic leads.
Next-Generation ATMP Development: Associate Prof. Dr. Trudy Straetemans spearheads the development of next-generation ATMPs, focusing on the integration of GMP simulation facilities within the Innovation Center of Advanced Therapies (ICAT). This pillar is crucial for ensuring the quality, safety and efficacy of new therapeutic modalities as they transition from the laboratory to clinical trials.
Cohorts and Clinical Trials: Dr. Moniek de Witte, a hematologist at the Department of Hematology, leads the critical work on cohorts and clinical trials, essential for validating the effectiveness and safety of new treatments. De Witte focuses on hematological malignancies within the context of allogeneic stem cell transplantation and other immune therapies. This work is pivotal for the translation of innovative therapies from bench to bedside, ensuring that new treatments can be safely and effectively integrated into clinical practice.
People
Principal Investigators at UMC Utrecht Tumorimmunology with different backgrounds such as biochemistry, biology, clinical translation and daily patient care work in close collaboration with academic and commercial partners to create innovative cancer therapies and treatments.
People
Principal Investigators at UMC Utrecht Tumorimmunology with different backgrounds such as biochemistry, biology, clinical translation and daily patient care work in close collaboration with academic and commercial partners to create innovative cancer therapies and treatments.
PRINCIPAL INVESTIGATORS
Achieving great things through strong teamwork.
Kuball Laboratories’ unique blend of academic insight and clinical application, spearheaded by a team of dedicated researchers, is driving forward the possibilities of cancer immunotherapy. By focusing on innovative therapeutic strategies and robust clinical trials, Kuball Laboratories is making significant strides in the battle against cancer, promising a new era of targeted, effective treatments with the potential to significantly improve patient outcomes.
Dennis Beringer
Kuball LABORATORIES
Jurgen Kuball
Kuball LABORATORIES
Moniek de Witte
Kuball LABORATORIES
Trudy Straetemans
Kuball LABORATORIES
Zsolt Sebestyen
Kuball LABORATORIES
MEMBERS
Emma Martinez-Sanchez (Project Manager)
Simone Punt (Project Manager)
Aiko Ballardini (Quality Control expert)
Angelo Meringa (PostDoc)
Anil Deshantri (Cell therapy production expert)
Caterina Riillo (PostDoc)
Lisanne Kempkes (Quality Assurance expert)
Patricia Hernandez-Lopez (PostDoc)
Peter Brazda (Computational Immunology)
Wout Weuring (Viral Vector Expert)
Yiteng Dang (PostDoc)
Farid Keramati (Computational biologist)
Anniek Stuut (PhD student)
Caroline Schwenzel (PhD student)
Laia Gasull (PhD student)
Lucrezia Gatti (PhD student)
Mara Nicolasen (PhD student)
Annet Daudeij (Technician)
Eva Mulder (Technician)
Sabine Heijhuurs (Technician)
Tineke Aarts (Technician)
Scientific and CLINICAL PARTNERS
The Tumorimmunology team at UMC Utrecht work closely with local hospitals and study and research groups to achieve their aim of developing groundbreaking treatment and therapies for cancer patients.
Scientific and CLINICAL PARTNERS
The Tumorimmunology team at UMC Utrecht work closely with local hospitals and study and research groups to achieve their aim of developing groundbreaking treatment and therapies for cancer patients.
Vacancies
Vacancies for positions at UMC Utrecht Tumorimmunology arise from time to time. We look forward to hearing from you!
Vacancies
Vacancies for positions at UMC Utrecht Tumorimmunology arise from time to time. We look forward to hearing from you!